Table 1.
Ongoing clinical studies of immune checkpoint inhibitors conducted for lung cancer in China.
| No. | Agents | Identifiers | Current status | Indications | Enrollment | Launched date |
|---|---|---|---|---|---|---|
| 1 | Nivolumab | CTR20200425 | Ongoing, not recruiting | Previously untreated locally advanced NSCLC | 888 | 4/3/2020 |
| CTR20180929 | Recruitment completed | NSCLC | 642 | 7/9/2018 | ||
| CTR20180914 | Recruiting | NSCLC | 420 | 7/9/2018 | ||
| CTR20171020 | Recruiting | NSCLC | 400 | 9/25/2017 | ||
| CTR20170694 | Recruitment completed | Extensive-stage SCLC | 907 | 7/24/2017 | ||
| CTR20170541 | Recruiting | Advanced or metastatic NSCLC (EGFR mutation+, T790M-, first-line TKI treatment failed) | 500 | 6/29/2017 | ||
| CTR20170304 | Recruiting | NSCLC | 721 | 4/13/2017 | ||
| CTR20160578 | Recruitment completed | Limited or extensive-stage NSCLC | 480 | 9/13/2016 | ||
| CTR20150767 | Recruitment completed | Advanced or metastatic NSCLC | 500 | 11/11/2015 | ||
| 2 | Pembrolizumab | CTR20191820 | Ongoing, not recruiting | Non-squamous NSCLC (EGFR-, ALK-) | 714 | 9/23/2019 |
| CTR20191591 | Recruiting | Neoadjuvant or adjuvant therapy of resectable | 570 | 9/16/2019 | ||
| Stage II B or III A NSCLC | ||||||
| CTR20191589 | Ongoing, not recruiting | First-line therapy of metastatic NSCLC with PD-L1+ | 620 | 8/12/2019 | ||
| CTR20181883 | Recruiting | Metastatic non-squamous NSCLC | 786 | 10/22/2018 | ||
| 3 | Durvalumab | CTR20200425 | Ongoing, not recruiting | Previously untreated locally advanced NSCLC | 888 | 4/3/2020 |
| CTR20190131 | Recruiting | Limited stage SCLC | 600 | 6/18/2019 | ||
| CTR20181576 | Recruiting | Locally advanced NSCLC | 360 | 4/8/2019 | ||
| CTR20170012 | Recruiting | Advanced NSCLC | 440 | 1/19/2017 | ||
| 4 | Atezolizumab | CTR20192714 | Ongoing, not recruiting | Extensive-stage SCLC | 200 | 2/17/2020 |
| CTR20190821 | Recruiting | Stage IV non-squamous NSCLC | 306 | 8/14/2019 | ||
| CTR20190668 | Recruiting | Locally advanced or metastatic NSCLC | 100 | 4/11/2019 | ||
| CTR20181628 | Ongoing, not recruiting | NSCLC | 302 | 11/7/2018 | ||
| CTR20180582 | Recruitment completed | Previously treated locally advanced or metastatic NSCLC | 621 | 7/2/2018 | ||
| CTR20171629 | Recruiting | Primary treatment of advanced or relapsed or metastatic NSCLC | 441 | 1/18/2018 | ||
| CTR20170064 | Recruitment completed | Previously untreated with chemotherapy stage IV non-squamous NSCLC | 578 | 4/6/2017 | ||
| CTR20160994 | Recruitment | Primary treatment of stage IV NSCLC with high expression of PD-L1 | 502 | 6/23/2017 | ||
| CTR20160988 | Recruitment completed | Stage III extensive-stage SCLC | 502 | 2/15/2017 | ||
| CTR20160510 | Recruiting | Completely resected stage IB-IIIA NSCLC | 760 | 1/11/2017 | ||
| 5 | Toripalimab | CTR20192525 | Ongoing, not recruiting | Recurrent and metastatic NSCLC | 124 | 12/19/2019 |
| CTR20192179 | Recruiting | Operative stage III NSCLC | 306 | 11/6/2019 | ||
| CTR20191139 | Recruiting | Extensive-stage SCLC | 406 | 4/11/2019 | ||
| CTR20190768 | Recruiting | Advanced NSCLC with positive EGFR sensitive mutation that failed TKI treatment | 350 | 4/19/2019 | ||
| CTR20190147 | Recruiting | Advanced NSCLC | 450 | 1/24/2019 | ||
| 6 | Sintilimab | CTR20192164 | Ongoing, not recruiting | Advanced NSCLC | 24 | 11/16/2019 |
| CTR20190972 | Recruiting | Non-squamous NSCLC | 480 | 6/14/2019 | ||
| CTR20190968 | Recruiting | Non-squamous NSCLC | 480 | 6/6/2019 | ||
| CTR20182559 | Active suspension | Non-squamous NSCLC | 480 | 1/22/2019 | ||
| CTR2018255 | Active suspension | Non-squamous NSCLC | 480 | 1/10/2019 | ||
| CTR20181437 | Recruitment completed | Advanced or metastatic NSCLC | 348 | 9/11/2018 | ||
| CTR20180975 | Recruitment | Non-squamous NSCLC | 378 | 7/23/2018 | ||
| completed | ||||||
| 7 | Camrelizumab | CTR20200638 | Ongoing, not recruiting | Relapse or metastasis PD-L1 positive NSCLC without systemic treatment | 762 | 4/13/2020 |
| CTR20200637 | Ongoing, not recruiting | Relapse or metastasis NSCLC without systemic treatment | 762 | 4/20/2020 | ||
| CTR20190113 | Recruiting | Stage IV non-squamous NSCLC with KRAS mutation | 230 | 2/13/2019 | ||
| CTR20181611 | Recruitment completed | Stage IV squamous NSCLC | 360 | 9/13/2018 | ||
| 8 | BGB-A317 | CTR20190511 | Recruiting | Extensive-stage SCLC | 364 | 5/17/2019 |
| CTR20181746 | Recruitment completed | Squamous NSCLC | 342 | 11/25/2019 | ||
| CTR20180292 | Recruitment completed | Squamous NSCLC | 342 | 7/26/2018 | ||
| CTR20180032 | Recruitment completed | Non-squamous NSCLC | 320 | 7/10/201 | ||
| CTR20171112 | Recruiting | NSCLC | 641 | 10/12/2017 | ||
| CTR20170361 | Recruitment completed | Lung cancer | 60 | 7/27/2017 | ||
| 9 | AK104 | CTR20191326 | Recruiting | Advanced solid tumor | 120 | 7/23/2019 |
| (NSCLC, melanoma, nasopharyngeal carcinoma, etc.) | ||||||
| 10 | KN046 | CTR20191219 | Recruiting | NSCLC | 50 | 6/25/2019 |
| CTR20190195 | Recruiting | NSCLC | 149 | 1/31/2019 |
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1; SCLC, small cell lung cancer; TKI